Please login to the form below

Not currently logged in
Email:
Password:

Chimerix

This page shows the latest Chimerix news and features for those working in and with pharma, biotech and healthcare.

Merck says drug for CMV in transplant patients hits targets

Merck says drug for CMV in transplant patients hits targets

The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of pivotal trials.

Latest news

  • Chimerix hit as lead drug brincidofovir flunks trial Chimerix hit as lead drug brincidofovir flunks trial

    Patients in the brincidofovir arm also showed an increase in mortality compared to the control arm, but the increase was not statistically significant, according to Chimerix. ... Both GVHD and use of corticosteroids are risk factors for 'late' CMV

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    Anti-infective deals. A similar size to the Genmab deal at $168m is the agreement between Chimerix, a US based private company developing antiviral therapies and Merck &Co. ... 178. Chimerix / Merck &Co. Licence. Lipid antiviral conjugate in phase 1 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Former Glaxo CEO Ernest Mario to chair Chimerix Former Glaxo CEO Ernest Mario to chair Chimerix

    Chimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman. ... Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics